Breast cancer outcomes in low- and middle-income countries: Interactions of tumor biology, clinical care, and health-system capacity-A structured narrative review with an Indonesian case study.
TL;DR
This structured narrative review examines how biological characteristics, stage at diagnosis, access to multimodality treatment, survivorship services, and health-system capacity interact in low- and middle-income countries (LMICs), with Indonesia developed as a country case study.
Abstract
Background
Breast cancer survival remains markedly unequal across countries, and the determinants of this gap extend beyond tumor biology. This structured narrative review examines how biological characteristics, stage at diagnosis, access to multimodality treatment, survivorship services, and health-system capacity interact in low- and middle-income countries (LMICs), with Indonesia developed as a country case study.
Methods
PubMed/MEDLINE and official World Health Organization (WHO), International Agency for Research on Cancer (IARC), Union for International Cancer Control (UICC), and Indonesian Ministry of Health sources were searched through 20 July 2026. Eligible evidence included international frameworks, systematic reviews, population-based studies, and regionally relevant observational studies addressing epidemiology, diagnosis, pathology, treatment, survivorship, financing, workforce, or cancer-control policy. Evidence was selected and interpreted using a structured narrative approach informed by SANRA principles.
Results
GLOBOCAN 2022 estimated 66,271 new female breast cancer cases and 22,598 deaths in Indonesia. Indonesian studies demonstrate substantial diagnostic delay, sociodemographic inequalities in stage at presentation, incomplete access to biomarker-directed care, radiotherapy waiting and completion problems, and financial misalignment between hospital costs and reimbursement. Across LMICs, younger patient age and heterogeneous subtype distributions may modify risk, but late diagnosis and failures across the care pathway frequently exert a larger population-level effect.
Conclusions
Improvement requires an integrated strategy rather than isolated interventions. The WHO Global Breast Cancer Initiative targets->60% of invasive cancers diagnosed at stage I-II, completion of diagnostic evaluation within 60 days, and >80% completion of recommended multimodality treatment-provide measurable anchors. For Indonesia, priorities are symptom-based early detection, rapid referral and tissue diagnosis, quality-assured ER/PR/HER2 testing, resource-stratified treatment pathways, radiotherapy expansion, patient navigation, survivorship integration, and stronger registry-linked accountability.